FDA panel recommends BMS's belatacept for kidney transplant rejection
This article was originally published in Scrip
Executive Summary
By a 13-to-5 vote, the US FDA's advisory committee on cardiovascular and renal drugs on March 1st recommended that the agency grant Bristol-Myers Squibb's biologics licence application for belatacept, to be used to prevent rejection of transplanted kidneys.